ADVA
ADVA (ISIN: DE0005103006), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported financial results for Q4 and full year 2019 ended on December 31, 2019. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200219006045/en/
Q4 2019 financial summary 1
(in thousands of EUR) |
Q4 |
Q4 |
Change |
Q3 |
Change |
|
|||
|
2019 |
2018 |
|
2019 |
|
|
|||
|
|
||||||||
Revenues |
151,135 |
131,513 |
14.9% |
144,310 |
4.7% |
|
|||
Pro forma gross profit |
54,633 |
48,665 |
12.3% |
49,086 |
11.3% |
|
|||
in % of revenues |
36.1% |
37.0% |
-0.9pp |
34.0% |
2.1pp |
|
|||
Pro forma operating income |
10,333 |
8,106 |
27.5% |
7,393 |
39.8% |
|
|||
in % of revenues |
6.8% |
6.2% |
0.6pp |
5.1% |
1.7pp |
|
|||
Operating income 2 |
5,438 |
6,332 |
-14.1% |
3,200 |
69.9% |
|
|||
Net income 2 |
2,522 |
3,633 |
-30.6% |
2,190 |
15.2% |
|
|||
|
|
|
|
|
|||||
(in thousands of EUR) |
Dec. 31 2019 |
Dec. 31 2018 |
Change |
Sep. 30 2019 |
Change |
|
|||
Cash and cash equivalents |
54,263 |
62,652 |
-13.4% |
38,396 |
41.3% |
|
|||
Net debt 3 |
61,146 |
26,832 |
127.9% |
74,873 |
-18.3% |
|
|||
1
Potential differences due to rounding
2
Q4 including EUR 3.2 million and Q3 including EUR 2.5 million one-off expenses
3
Q4 2019 including EUR 34.4 million and Q3 2019 including EUR 36.2 million lease liabilities due to first-time adoption of IFRS 16
Q4 2019 IFRS financial results
Revenues for Q4 2019 increased by 4.7% to EUR 151.1 million from EUR 144.3 million in Q3 2019 and grew significantly by 14.9% from EUR 131.5 million in the same year-ago period. Revenues for Q4 2019 were at the upper end of the guidance corridor the company provided on October 24, 2019, of between EUR 142 million and EUR 152 million.
Pro forma operating income for Q4 2019 was EUR 10.3 million (6.8% of revenues), up from EUR 7.4 million (5.1% of revenues) in Q3 2019 and above EUR 8.1 million (6.2% of revenues) in the same year-ago period. Pro forma operating income for Q4 2019 was also at the upper end of the company’s guidance range of between 5% and 7% of revenues.
Operating income for Q4 2019 of EUR 5.4 million increased from EUR 3.2 million reported for Q3 2019 but decreased compared to EUR 6.3 million in the same year-ago quarter. This is mainly due to tariffs on China-made products in the US market, the strength of the US dollar and one-off expenses of EUR 3.2 million in Q4 2019. These one-off expenses are primarily driven by selective head count reduction and site closures.
Net income for Q4 2019 was EUR 2.5 million and increased by 15.2% from EUR 2.2 million in Q3 2019; however, it declined from EUR 3.6 million in Q4 2018.
At quarter-end, the company’s cash and cash equivalents totaled EUR 54.3 million, representing a substantial increase of 41.3% compared to EUR 38.4 million at the end of Q3 2019.
The company’s net debt decreased by EUR 13.8 million to EUR 61.1 million from EUR 74.9 million at the end of Q3 2019.
Net working capital at quarter-end was EUR 128.2 million compared to EUR 137.8 million at the end of Q3 2019. Although revenues increased in Q4, ADVA managed to decrease net working capital by EUR 9.6 million, mainly due to reduction of trade account receivables.
2019 annual summary 1
(in thousands of EUR) |
2019 |
2018 |
Change |
|
|
Revenues |
556,821 |
501,981 |
10.9% |
|
|
Pro forma gross profit |
195,364 |
185,621 |
5.2% |
|
|
in % of revenues |
35.1% |
37.0% |
-1.9pp |
|
|
Pro forma operating income |
24,811 |
23,266 |
6.6% |
|
|
in % of revenues |
4.5% |
4.6% |
-0.1pp |
|
|
Operating income 2 |
12,003 |
14,989 |
-19.9% |
|
|
Net income |
7,045 |
9,678 |
-27.2% |
|
|
|
|
||||
(in thousands of EUR) |
Dec. 31 2019 |
Dec. 31 2018 |
Change |
|
|
Cash and cash equivalents |
54,263 |
62,652 |
-13.4% |
|
|
Net debt 3 |
61,146 |
26,832 |
127.9% |
|
|
1
Potential differences due to rounding
2
2019 including EUR 5.7 million one-off expenses
3
2019 including EUR 34.4 million lease liabilities due to first-time adoption of IFRS 16
For the full year 2019, revenues increased by 10.9% to EUR 556.8 million from EUR 502.0 million in 2018. The positive development is due to solid demand from all customer groups across all technology areas. Except for Q1 2019, quarterly revenues increased sequentially in 2019.
Pro forma gross profit increased by 5.2% from EUR 185.6 million in 2018 to EUR 195.4 million in 2019. Pro forma gross margin, however, decreased from 37.0% in 2018 to 35.1% in 2019. The margin was impacted by the US tariffs on Chinese-made goods in the US market and the strong US dollar.
Pro forma operating income for 2019 was EUR 24.8 million (4.5% of revenues), compared to EUR 23.3 million (4.6% of revenues) in 2018. Operating income for 2019 was EUR 12.0 million compared to EUR 15.0 million in 2018 and decreased by EUR 3.0 million. Operating income 2019 includes one-off expenses of EUR 5.7 million. These one-off expenses are primarily driven by selective head count reduction and site closures.
In 2019, ADVA generated a net income of EUR 7.0 million, down by EUR 2.7 million after EUR 9.7 million in the prior year.
Basic and diluted earnings per share in 2019 amounted to positive EUR 0.14, both compared to basic and diluted earnings per share of EUR 0.19 in 2018.
Management commentary
“Today, we report one of the best results in our 25-year company history,” commented Uli Dopfer, CFO, ADVA. “Both of our two key metrics were at the upper end of our guidance range, and year-over-year we increased revenues significantly by 14.9%. On an annualized basis our revenue grew by more than 10% – an excellent result that even exceeded our self-imposed goals and was supported by satisfactory profitability. We are finalizing our restructuring and preparing for the uncertainty caused by COVID-19. It is currently difficult for us to assess what impact the crisis in China will have on our 2020 results. The city of Wuhan is an important center for photonic components and subsystems, and the isolation of the region will lead to delays in the global supply chain. We expect that despite the healthy order backlog, some of the order fulfillment and revenue recognition will shift from Q1 2020 to later quarters. However, in light of the positive order entry and strong demand, we are very confident of further increasing annual revenues and profitability compared to 2019.”
“Numerous factors that caused market uncertainty and tension in the past year will continue to be relevant in 2020. However, we adjusted very well to the new boundary conditions and once again showed that the DNA of our company guarantees stable and reliable results even in difficult times,” said Brian Protiva, CEO, ADVA. “Despite the trade tensions, we held our course and developed our business with great discipline. Throughout the year we were able to sequentially increase our revenues and gain market share in certain segments. ADVA is in an excellent position for the coming years. We have created a solid basis in all three technology areas and see interesting growth scenarios as a result of transformational change disrupting our markets.”
2020 financial outlook
For the full year 2020, ADVA expects revenues to exceed EUR 580 million and a pro forma operating income of greater than 5% of revenues.
The company will publish its financial results for Q1 2020 on April 23, 2020.
Conference call details
ADVA will hold a conference call for analysts and investors today, February 20, 2020, to discuss these results and management’s outlook. The company’s CEO, Brian Protiva, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CET (9:00 a.m. EDT). A question and answer session will follow management presentations.
To participate, please dial the appropriate number at least five minutes before the start time and ask for the ADVA conference call.
International number: +49 69 201 744 210
US number: +1 877 423 0830
Pin code: 743 752 65#
A corresponding presentation is available on ADVA’s website:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls
The complete annual report 2019 (January – December) is available as a PDF here:
https://www.adva.com/en/about-us/investors/financial-results/financial-statements
A replay of the call will be available here:
https://www.adva.com/en/about-us/investors/financial-results/conference-calls
Forward-looking statements
The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.
Use of pro forma financial information
ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, expenses related to restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200219006045/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
